Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).
Diego Casas DezaAna Belén Julián GomaraEva Caudevilla BiotaBelén BeltránEugeni DomènechAna Gutiérrez CasbasMiriam MañosaYamile ZabanaLourdes Roc AlfaroEmilio Valverde RomeroElena García GonzálezBeatriz SiciliaViviana LaredoMaria José Alcalá EscricheLucia Madero VelázquezRocío Ferreiro-IglesiasAntonia Palmero PérezMargalida CalafatSaioa Rubio IturriaIrene Moraleja YudegoYolanda Ber NietoSandra García MateoJavier P GisbertRaquel Vicente LidónLara AriasErika AlfambraAna Belén Doñate BoraoElena Peña GonzálezPilar Corsino RocheMiren Vicuña ArreguiAinara ElorzaManuel Domínguez CajalMaría ChaparroManuel Barreiro-de AcostaSantiago García-LópezPublished in: Gastroenterologia y hepatologia (2024)
Mesalazine does not have a negative effect on the response to SARS-CoV-2 vaccines in IBD patients.